Identification of novel truncated Androgen Receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory Prostate Cancer (PCa) cell line

Human Mutation

Volumn 31, Issue 1, 2010, Pages 74-80

  Marcias, Gemma ^a   Erdmann, Eva ^a   Lapouge, Gaëlle ^b   Siebert, Christelle ^a   Lémy, Philippe Barthé ^a,c   Duclos, Brigitte ^c   Bergerat, Jean Pierre ^a,c   Raline, Jocelyn Cé ^a,c   Kurtz, Jean Emmanuel ^a,c  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

22Rv1; Aberrant splicing; Androgen receptor; AR; PCa; Prostate cancer; Truncated receptor

Indexed keywords

ANDROGEN RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; EXON; EXPERIMENTAL MODEL; GENE DUPLICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC CODE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MUTANT; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; RNA SPLICING; RNA TRANSCRIPTION;

EID: 74049109753     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.21138     Document Type: Article

References (14)

1. Bergerat JP, Céraline J. 2009. Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 30:145-157.
2. Céraline J, Erdmann E, Erbs P, Deslandres-Cruchant M, Jacqmin D, Duclos B, Klein-Soyer C, Dufour P, Bergerat JP. 2003. A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer. Eur J Endocrinol 148:99-111.
3. Céraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP. 2004. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgenindependent growth in prostate cancer. Int J Cancer 108:152-157.
4. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. 2008. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68: 5469-5477.
5. Grosclaude P, Velten M. 2007. Prostate. In: Grosclaude P, Bossard N, Remontet L, Belot A, Arveux P, Bouvier AM, Launoy G, Maynadie M, Velten M, Faivre J, Esteve J, editors. Survie des patients atteints de cancer en France. E ́ tude des registres du réseau FRANCIM. Survie des patients atteints de cancer en France. Paris: Springer. p 273-281.
6. Haelens A, Verrijdt G, Callewaert L, Christiaens V, Schauwaers K, Peeters B, Rombauts W, Claessens F. 2003. DNA recognition by the androgen receptor: evidence for an alternative DNA-dependent dimerization, and an active role of sequences flanking the response element on transactivation. Biochem J 369:141-151.
7. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys H, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. 2009. Ligand-independent androgen receptor variants derived form splicing of cryptic exons signify hormone refractory prostate cancer. Cancer Res 69:16-22.
8. Jagla M, Féve M, Kessler P, Lapouge G, Erdmann E, Serra S, Bergerat JP, Céraline J. 2007. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology. 148: 4334-4343.
9. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. 2006. Cancer statistics. CA Cancer J Clin 56:106-130.
10. Shang Y, Myers M, Brown M. 2002. Formation of the androgen receptor transcription complex. Mol Cell 9:601-610; Erratum: Mol Cell 2003;11:1697.
11. Sramkoski RM, Pretlow II TG, Giaconia JM, Pretlow TP, Schwartz S, Man-Sun S, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. 1999. A new human prostate cell line, 22Rv1. In Vitro Cell Dev Biol 35:403-409.
12. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ. 2002. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 62:6606-6614.
13. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. 2007. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27:380-392.
14. Wickert L, Selbig J. 2002. Structural analysis of the DNA-binding domain of alternatively spliced steroid receptors. J Endocrinol 173:429-436.